Literature DB >> 27061135

Lymph node metastasis of primary endometrial cancers: Associated proteins revealed by MALDI imaging.

Parul Mittal1,2, Manuela Klingler-Hoffmann1,2, Georgia Arentz1,2, Lyron Winderbaum1,2, Noor A Lokman1,3, Chao Zhang1,2, Lyndal Anderson4, James Scurry5, Yee Leung6, Colin Jr Stewart6, Jonathan Carter7, Gurjeet Kaur8, Martin K Oehler3,9, Peter Hoffmann1,2.   

Abstract

Metastasis is a crucial step of malignant progression and is the primary cause of death from endometrial cancer. However, clinicians presently face the challenge that conventional surgical-pathological variables, such as tumour size, depth of myometrial invasion, histological grade, lymphovascular space invasion or radiological imaging are unable to predict with accuracy if the primary tumour has metastasized. In the current retrospective study, we have used primary tumour samples of endometrial cancer patients diagnosed with (n = 16) and without (n = 27) lymph node metastasis to identify potential discriminators. Using peptide matrix assisted laser desorption/ionisation mass spectrometry imaging (MALDI-MSI), we have identified m/z values which can classify 88% of all tumours correctly. The top discriminative m/z values were identified using a combination of in situ sequencing and LC-MS/MS from digested tumour samples. Two of the proteins identified, plectin and α-Actin-2, were used for validation studies using LC-MS/MS data independent analysis (DIA) and immunohistochemistry. In summary, MALDI-MSI has the potential to identify discriminators of metastasis using primary tumour samples.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Biomarker; Endometrial cancer; Lymph node metastasis; Proteomics

Mesh:

Substances:

Year:  2016        PMID: 27061135     DOI: 10.1002/pmic.201500455

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  6 in total

1.  Balancing sufficiency and impact in reporting standards for mass spectrometry imaging experiments.

Authors:  Ove J R Gustafsson; Lyron J Winderbaum; Mark R Condina; Berin A Boughton; Brett R Hamilton; Eivind A B Undheim; Michael Becker; Peter Hoffmann
Journal:  Gigascience       Date:  2018-10-01       Impact factor: 6.524

2.  Moving translational mass spectrometry imaging towards transparent and reproducible data analyses: a case study of an urothelial cancer cohort analyzed in the Galaxy framework.

Authors:  Peter Bronsert; Oliver Schilling; Melanie Christine Föll; Veronika Volkmann; Kathrin Enderle-Ammour; Sylvia Timme; Konrad Wilhelm; Dan Guo; Olga Vitek
Journal:  Clin Proteomics       Date:  2022-04-19       Impact factor: 5.000

3.  Site-to-Site Reproducibility and Spatial Resolution in MALDI-MSI of Peptides from Formalin-Fixed Paraffin-Embedded Samples.

Authors:  Alice Ly; Rémi Longuespée; Rita Casadonte; Petra Wandernoth; Kristina Schwamborn; Christine Bollwein; Christian Marsching; Katharina Kriegsmann; Carsten Hopf; Wilko Weichert; Jörg Kriegsmann; Peter Schirmacher; Mark Kriegsmann; Sören-Oliver Deininger
Journal:  Proteomics Clin Appl       Date:  2019-01-04       Impact factor: 3.494

4.  Sample preparation of formalin-fixed paraffin-embedded tissue sections for MALDI-mass spectrometry imaging.

Authors:  Heidi Noels; Vera Jankowski; Joachim Jankowski; Juliane Hermann; Wendy Theelen; Michaela Lellig; Setareh Orth-Alampour; Peter Boor
Journal:  Anal Bioanal Chem       Date:  2020-01-28       Impact factor: 4.142

Review 5.  Plectin in Cancer: From Biomarker to Therapeutic Target.

Authors:  Samantha M Perez; Lindsey T Brinton; Kimberly A Kelly
Journal:  Cells       Date:  2021-08-30       Impact factor: 6.600

6.  A Protocol for the Acquisition of Comprehensive Proteomics Data from Single Cases Using Formalin-Fixed Paraffin Embedded Sections.

Authors:  Mitchell Acland; Parul Mittal; Georgia Arentz; Fergus Whitehead; Peter Hoffmann; Manuela Klingler-Hoffmann; Martin K Oehler
Journal:  Methods Protoc       Date:  2022-07-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.